Reuters -- Cytos Biotechnology’s anti-smoking vaccine missed its main target in a mid-stage study, making it highly unlikely the product will reach the market and slamming the Swiss group’s shares.
Reuters -- Cytos Biotechnology’s anti-smoking vaccine missed its main target in a mid-stage study, making it highly unlikely the product will reach the market and slamming the Swiss group’s shares.
